Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $13.00 to $21.00. They now have a "buy" rating on the stock.
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress [Yahoo! Finance]